PRM Pharma Launches HemiClor: A Milestone in Hypertension Treatment

PRM Pharma Launches HemiClor®: A Milestone in Hypertension Treatment

PRM Pharma, LLC has announced the nationwide availability of HemiClor® (chlorthalidone) 12.5 mg tablets, marking a significant development in hypertension treatment. This product is distinguished as the first and only FDA-approved low-dose chlorthalidone formulation specifically designed for managing hypertension in adults.

The release of HemiClor aligns with the recently updated 2025 AHA/ACC Guidelines for hypertension management, which underscore chlorthalidone's importance as a long-acting, thiazide-like diuretic. The guidelines recommend maximizing diuretic therapy by substituting hydrochlorothiazide with chlorthalidone doses of either 12.5 mg or 25 mg for patients suffering from resistant hypertension. Notably, the prevalence of resistant hypertension among hypertensive adults in the U.S. ranges from 8.5% to 20%. This condition is linked to significantly increased risks of major cardiovascular events, including myocardial infarction, strokes, and renal failure.

The latest guidelines emphasize that antihypertensive treatment should ideally start with a combination of agents, notably an ACE inhibitor or an ARB, a calcium channel blocker, and a diuretic. Replacing standard thiazide diuretics with chlorthalidone can offer improved blood pressure reduction and additional cardiovascular protection, especially for patients with a history of heart attacks or strokes.

Chlorthalidone’s prolonged half-life and robust cardiovascular outcome data have made it a cornerstone in hypertension management for over five decades. Landmark studies like ALLHAT and SHEP have demonstrated significant reductions in cardiovascular events from early treatment regimens incorporating once-daily chlorthalidone at low doses. Previous guidelines have endorsed starting therapy with doses ranging from 12.5 mg to 25 mg daily.

Dr. Michael Ernst, a Clinical Professor at the University of Iowa, commented, "Despite its decades-long history of proven benefits, the absence of a low-dose formulation hindered us from optimizing chlorthalidone’s use in clinical practice. The launch of HemiClor® enables us to leverage the historical evidence to enhance patient care efficiently."

Dr. William B. White, Professor Emeritus at the University of Connecticut, also expressed optimism regarding the availability of HemiClor in the U.S., stating, "This new 12.5 mg option will provide clinicians with the necessary flexibility to initiate treatment in line with contemporary clinical recommendations—especially for patients classified as stage 1 or stage 2 hypertensive."

Officially approved by the FDA on March 17, 2025, HemiClor is now accessible in pharmacies nationwide. Various pharmacy savings programs, including SaveHealth, GoodRx, and others, are available to assist eligible patients in managing their medication costs. For instance, SaveHealth may allow a 30-day supply of HemiClor to be purchased for as little as $12.15, although prices are subject to change.

Important Safety Information

HemiClor® is indicated for hypertension treatment, effectively lowering blood pressure and thereby reducing the risk of fatal and nonfatal cardiovascular incidents. However, the use of HemiClor is contraindicated in patients with anuria or those who have hypersensitivity to chlorthalidone or sulfonamide-derived medications. Typical adverse reactions include electrolyte imbalances, dizziness, and gastrointestinal discomfort. Additionally, ongoing monitoring of serum electrolytes is advised to ensure patient safety.

For medical professionals and patients interested in learning more, comprehensive prescribing information is available at HemiClor.com, which includes detailed efficacy data and safety information for safe medication practice.

In summary, the introduction of HemiClor marks a pivotal evolution in the management of hypertension, aligning with contemporary clinical practices and offering patients and healthcare providers a valuable new tool in the fight against high blood pressure.